# Lumexa Imaging Holdings, Inc. (LMRI)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/lumexa-imaging-holdings-inc/ JSON: https://steadybase.io/company/lumexa-imaging-holdings-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: Lumexa Imaging Holdings, Inc.
- Ticker: LMRI (Nasdaq)
- SEC CIK: 0002071288
- Industry: Services-Medical Laboratories (SIC 8071)
- Headquarters: Raleigh, NC
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Emerging growth company
- Website: lumexaimaging.com
- Investor relations: https://ir.lumexaimaging.com/
- LinkedIn: https://www.linkedin.com/company/lumexa-imaging
- Next earnings date: Nov 10, 2026

## Key facts

- Shares outstanding: 96,074,976 as of Aug 12, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526348902/0001193125-26-348902-index.html

## Business

We are one of the largest national providers of diagnostic imaging services. Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of December 31, 2025, we and our affiliates operated the second largest1 outpatient imaging center footprint in the United States.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm

## Officers and directors

- Caitlin Zulla, Chief Executive Officer and Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- J. Anthony Martin, Chief Financial Officer. LinkedIn: https://linkedin.com/in/tony-martin-60b7842b7. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- James Anthony Martin, Chief Financial Officer. Source: Form 4 filed Jan 15, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000090514826000196/0000905148-26-000196-index.htm
- James E. Walker, Jr., Chief Accounting Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- James Edward Walker Jr., Principal Accounting Officer. Source: Form 4 filed Feb 27, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526083296/0001193125-26-083296-index.htm
- Julie Szeker, Chief Legal Officer & Corp Sec. Source: Form 4 filed Dec 16, 2025, https://www.sec.gov/Archives/edgar/data/2071288/000090514825004386/0000905148-25-004386-index.htm
- Russell Stewart, Chief Medical Officer. LinkedIn: https://linkedin.com/in/russell-stewart-md-mba-ms-71a71417. Source: Form 4 filed Dec 16, 2025, https://www.sec.gov/Archives/edgar/data/2071288/000090514825004387/0000905148-25-004387-index.htm
- Lee Cooper, Chair of the Board. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- Brett Brodnax, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- Brian Regan, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- Bridget Karlin, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- Glenn Eisenberg, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- Molly Joseph, Lead Independent Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm

## Recent 8-K events

- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/d113773d8k.htm
- Jun 30, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526290788/d155301d8k.htm
- Jun 12, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526269379/d127553d8k.htm
- May 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526219415/d145661d8k.htm
- Apr 9, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526149837/d81221d8k.htm
- Mar 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526124978/d138307d8k.htm
- Mar 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526084047/d40982d8k.htm
- Jan 15, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526013511/d44183d8k.htm
- Dec 18, 2025: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312525324774/d54354d8k.htm
- Dec 12, 2025: Item 1.01, Entry into a material definitive agreement; Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312525317521/d25072d8k.htm

## Insider trades (Form 4)

- May 19, 2026: Brett Brodnax (Director) bought 35,000 shares, about $253,750. Source: https://www.sec.gov/Archives/edgar/data/2071288/000090514826002611/0000905148-26-002611-index.htm
- May 14, 2026: Henry Lee Cooper (Director) bought 30,000 shares, about $223,200. Source: https://www.sec.gov/Archives/edgar/data/2071288/000090514826002503/0000905148-26-002503-index.htm

## What management said

- "During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers" Caitlin Zulla, Chief Executive Officer of Lumexa Imaging (8-K filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/d113773dex991.htm

## Latest filings

- 8-K filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/2071288/000119312526346813/d113773d8k.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/2071288/000119312526131907/lmri_10k_2025.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/2071288/000119312526348902/lmri-20260630.htm
- DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/2071288/000119312526187316/d72565ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/